REMARKS

Entry of the above amendments is respectfully requested. Upon entry of these amendments, this application will contain claims 1-16 and 27-53 pending and under consideration. The application was originally filed with claims 1-29. In this submission, claims 17-26 have been canceled, and new claims 30-53 have been added.

In response to the Restriction Requirement dated June 25, 2004, The Applicant elects to pursue the invention of Group I, claims 1-16 and 27-29, drawn to a composition. Further, the Applicant provisionally elects to pursue, with traverse, the species of phytol derivatives. Claims 4-16 and 27-29 read on at least this species. It is believed that new claims 30-49 also read on at least the elected species.

Furthermore, the Applicant submits that claim 1 is a generic claim including phytol, isophytol, and phytol derivatives within its scope. Therefore, the Applicant maintains that each of the three species should be examined together in the current application. The Applicant is allowed a reasonable number of species to be examined together pursuant to 37 CFR §1.146. Furthermore, it is maintained that the examination of all three species together will not present a serious burden to the Examiner.

New claims 50-53 are directed to a method of enhancing the immunogenicity of a vaccine or to a method of treating a patient. Consideration of these claims are requested under §MPEP 821.04 when claims to the composition are found to be allowable

It is believed that claims 1-16 and 27-53 are in condition for allowance. Reconsideration of the present application is respectfully requested. The Examiner is invited to contact the undersigned attorney by telephone if there are any questions about this Response or other issues that may be resolved in that fashion.

Respectfully submitted,

Bv:

James B. Myers, Reg. No. 42,021

Woodard, Emhardt, Moriarty, McNett & Henry LLP

3700 Bank One Center Tower

111 Monument Circle

Indianapolis, IN 46204-5137

(317) 713-4948

Page 9 of 9